A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive ...

Background. A 61-year-old patient with no relevant medical or family history presented with a 2 month history of refractory dry cough that led to the diagnosis of typical carcinoid tumor of the ...

After a review by the neuroendocrine ... carcinoid tumor. Carcinoid tumors commonly originate in the gastrointestinal tract with an incidence ranging from 2.5 to 5 cases per 100,000 population. 1 ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment ...

NET are heterogeneous tumors that arise from the neuroendocrine ... in 1% of CABOMETYX patients. Monitor for signs and symptoms, and discontinue CABOMETYX in patients with Grade 4 fistulas or ...

1 The drug is indicated to treat ... clinical director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute ...

Median PFS among 99 patients with pNET who were randomized 2:1 to receive cabozantinib or ... progression…regardless of primary tumor site and grade. Sharon Worcester, MA, is an award-winning ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...